Literature DB >> 31808840

Diagnostic workflow for hereditary erythrocytosis and thrombocytosis.

Mary Frances McMullin1.   

Abstract

In the patient presenting with an elevated blood count who does not have an acquired clonal disorder causing a myeloproliferative neoplasm, hereditary erythrocytosis or hereditary thrombocytosis needs to be considered as a possible explanation. A young patient and/or those with a family history of myeloproliferative neoplasm should specifically raise this possibility. Among the causes of hereditary erythrocytosis are mutations in the genes in the oxygen sensing pathway and high-affinity hemoglobins. Hereditary thrombocytosis has been shown to be accounted for by mutations in THPO, MPL, and JAK2 genes. In those who have a possible hereditary erythrocytosis or thrombocytosis, the investigative pathway includes specific investigation to rule out the more common acquired clonal disorders, and, if indicated, other secondary causes, measurement of specific cytokines as indicated, and search for specific identified molecular lesions that have been shown to cause these hereditary disorders. There remain individuals who appear to have a hereditary disorder in whom a genetic lesion cannot currently be identified.
© 2019 by The American Society of Hematology. All rights reserved.

Entities:  

Year:  2019        PMID: 31808840      PMCID: PMC6913500          DOI: 10.1182/hematology.2019000047

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  40 in total

1.  Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Authors:  Ashot S Harutyunyan; Roberto Giambruno; Christian Krendl; Alexey Stukalov; Thorsten Klampfl; Tiina Berg; Doris Chen; Jelena D Milosevic Feenstra; Roland Jäger; Bettina Gisslinger; Heinz Gisslinger; Elisa Rumi; Francesco Passamonti; Daniela Pietra; André C Müller; Katja Parapatics; Florian P Breitwieser; Richard Herrmann; Jacques Colinge; Keiryn L Bennett; Giulio Superti-Furga; Mario Cazzola; Emma Hammond; Robert Kralovics
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

Review 2.  A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

Authors:  Mary Frances McMullin; Claire N Harrison; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper S; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Adam J Mead
Journal:  Br J Haematol       Date:  2018-11-27       Impact factor: 6.998

3.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

4.  Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Authors:  Tiziano Barbui; Jürgen Thiele; Alessandra Carobbio; Paola Guglielmelli; Alessandro Rambaldi; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

5.  Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene.

Authors:  N Ghilardi; A Wiestner; M Kikuchi; A Ohsaka; R C Skoda
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

6.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Authors:  David A Hinds; Kimberly E Barnholt; Ruben A Mesa; Amy K Kiefer; Chuong B Do; Nicholas Eriksson; Joanna L Mountain; Uta Francke; Joyce Y Tung; Huong Marie Nguyen; Haiyu Zhang; Linda Gojenola; James L Zehnder; Jason Gotlib
Journal:  Blood       Date:  2016-06-30       Impact factor: 22.113

7.  Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.

Authors:  A de la Chapelle; A L Träskelin; E Juvonen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

8.  Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

Authors:  Caroline Marty; Cécile Saint-Martin; Christian Pecquet; Sarah Grosjean; Joseph Saliba; Céline Mouton; Emilie Leroy; Ashot S Harutyunyan; Jean-François Abgrall; Rémi Favier; Aurélie Toussaint; Eric Solary; Robert Kralovics; Stefan N Constantinescu; Albert Najman; William Vainchenker; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

9.  Erythrocytosis associated with a novel missense mutation in the BPGM gene.

Authors:  Nayia Petousi; Richard R Copley; Terence R J Lappin; Sally E Haggan; Celeste M Bento; Holger Cario; Melanie J Percy; Peter J Ratcliffe; Peter A Robbins; Mary Frances McMullin
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

10.  Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Authors:  Adam J Mead; Onima Chowdhury; Christian Pecquet; Alexandra Dusa; Petter Woll; Deborah Atkinson; Adam Burns; Joannah Score; Michelle Rugless; Ruth Clifford; Simon Moule; Nicola Bienz; Paresh Vyas; Nick Cross; Rosemary E Gale; Shirley Henderson; Stefan N Constantinescu; Anna Schuh; Sten Eirik W Jacobsen
Journal:  Blood       Date:  2013-03-27       Impact factor: 22.113

View more
  5 in total

1.  Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.

Authors:  James Bussel; Nicole Kucine
Journal:  Br J Haematol       Date:  2021-08-02       Impact factor: 8.615

2.  Manifestations and Related Risk Factors of Thrombocyte Abnormalities in HIV-Positive Patients Before and After the Initiation of ART.

Authors:  Bei Li; Leidan Zhang; Ying Liu; Jing Xiao; Xinyue Wang; Yuqing Wei; Lina Fan; Yujiao Duan; Guoli Li; Yaxian Kong; Hongxin Zhao
Journal:  Infect Drug Resist       Date:  2021-11-17       Impact factor: 4.003

3.  rs779805 Von Hippel-Lindau Gene Polymorphism Induced/Related Polycythemia Entity, Clinical Features, Cancer Association, and Familiar Characteristics.

Authors:  Gyula Remenyi; Zsuzsanna Bereczky; Réka Gindele; Aniko Ujfalusi; Arpad Illes; Miklos Udvardy
Journal:  Pathol Oncol Res       Date:  2021-11-26       Impact factor: 3.201

4.  Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis.

Authors:  Rushad Machhi; Ashley M Cunningham; Kenneth Hennrick; Karen A Schaser; Eliot C Williams; William Nicholas Rose
Journal:  Case Rep Hematol       Date:  2022-08-11

5.  EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.

Authors:  R J Leguit; A Orazi; N Kucine; H M Kvasnicka; U Gianelli; D A Arber; A Porwit; M Ponzoni
Journal:  Virchows Arch       Date:  2022-07-11       Impact factor: 4.535

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.